Search

Displaying results 541 - 550 of 4591 in total
  1. Drug

    Tixagevimab

    go.drugbank.com/drugs/DB16394
    ApprovedInvestigational

    [A243351, A243361, L39411] Tixagevimab is not approved for any indication by the FDA. … [L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022.

  2. Drug

    Trametinib

    go.drugbank.com/drugs/DB08911
    ApprovedInvestigational

    Originally developed by Japan Tobacco, trametinib was initially investigated for treating inflammation, but further studies for this indication were not pursued.[A258298] … [A258298] It was later approved by Health Canada on July 18, 2013 [L45588] and by the European Commission on June 30, 2014.

  3. Drug

    Upadacitinib

    go.drugbank.com/drugs/DB15091
    ApprovedInvestigational

    [A189165] Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies. … More recently, it has also been approved for the treatment of giant cell arteritis in adults and active polyarticular juvenile idiopathic arthritis in patients aged 2 years and older.[L10896]

  4. Drug

    Ethchlorvynol

    go.drugbank.com/drugs/DB00189
    ApprovedIllicitWithdrawn

    It has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists.

  5. Drug

    Dalbavancin

    go.drugbank.com/drugs/DB06219
    ApprovedInvestigational

    Modifications from these older glycoprotein classes facilitated a similar mechanism of action for dalbavancin but with increased activity and once-weekly dosing [FDA Label, F2356, A4072, A4073]. … Dalbavancin acts by interfering with bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of nascent cell wall peptidoglycan and preventing cross-linking [FDA Label, F2356, A4072

  6. Drug

    Clostridium tetani toxoid antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10583
    ApprovedInvestigational

    It is used for active immunization of children 7 years of age or older, and adults, for prevention of tetanus. … The toxoid in the Clostridium tetani culture is grown and detoxified followed by purification via ammonium sulfate filtration and precipation.

  7. Drug

    Bevacizumab

    go.drugbank.com/drugs/DB00112
    ApprovedInvestigational

    [A286054] This off-label practice was formalized with the approval of Lytenava (bevacizumab-vikg in the US; bevacizumab gamma in the EU/UK), the first ophthalmic formulation of bevacizumab developed specifically … [A193272,A193275,L12648] Avastin was subsequently approved by Health Canada on March 24, 2010 and by the European Commission on April 21, 2021.

  8. Drug

    Sodium stibogluconate

    go.drugbank.com/drugs/DB05630
    ApprovedInvestigational

    Sodium stibogluconate is sold in the UK as Pentostam (manufactured by GlaxoSmithKline). … Sodium stibogluconate is a medicine used to treat leishmaniasis and is only available for administration by injection. It belongs to the class of medicines known as the pentavalent antimonials.

  9. Drug

    Iobenguane

    go.drugbank.com/drugs/DB06704
    ApprovedInvestigational

    Iodine 123 is a cyclotron-produced radionuclide that decays to Te 123 by electron capture. Images are produced by a I123 MIBG scintigraphy. FDA approved on September 19, 2008.

  10. Drug

    Maralixibat

    go.drugbank.com/drugs/DB16226
    ApprovedInvestigational

    [L44396] On July 21, 2023, maralixibat was also approved by Health Canada.[L47541]